
This version is available at https://strathprints.strath.ac.uk/61007/

Strathprints is designed to allow users to access the research output of the University of Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Please check the manuscript for details of any other licences that may have been applied. You may not engage in further distribution of the material for any profitmaking activities or any commercial gain. You may freely distribute both the url (https://strathprints.strath.ac.uk/) and the content of this paper for research or private study, educational, or not-for-profit purposes without prior permission or charge.

Any correspondence concerning this service should be sent to the Strathprints administrator: strathprints@strath.ac.uk
Validation of a fully integrated platform and disposable microfluidic chips enabling parallel purification of genome segments for assembly

M. Kersaudy-Kerhoas¹, F. Amalou¹, Y. Liu¹, A. Che², J. Kelly², M.P.Y. Desmulliez³ and W. Shu¹,a)

1 Institute of Biological Chemistry, Biochemistry and Bioengineering, Heriot-Watt University, Edinburgh, United Kingdom.

2 Gingko Bioworks, 27 Drydock Avenue Floor, Boston, MA, USA

3 Institute of Sensors, Signals and Systems, Heriot-Watt University, Edinburgh, United Kingdom.

a) Corresponding author. w.shu@hw.ac.uk phone: 00 44 131 451 8165
Abstract

Recent progress in the field of genetic engineering has opened up the door to novel synthetic biology applications. Microfluidic technology has been emphasized as a key technology to support the development of these applications. While several important synthetic biology protocols have been developed in microfluidic format, no study has yet demonstrated on-chip error control. In synthetic biology protocols, the purification phase is a critical error control process which enhances the reliability of the genome segment assembly by removing undesired oligos. In this context, we report the design and characterization of a fully integrated platform, demonstrating the purification of up to 4 genome segments in parallel, prior to their off-chip assembly. The key innovation of this platform is the decoupling control strategy which eliminates the need to integrate expensive components onto the microfluidic device, enabling lower cost, disposability and rapid operation. Unlike most microfluidic chips where fluid connector plugs are needed to connect external pumps, this approach is plug-less and the chips are simply connected to the control breadboard by clamping. Furthermore the passive chip is isolated from the active control layer thereby eliminating the risk of sample-to-sample contamination in the reusable parts. As a validation of this fully-integrated system, the parallel on-chip purification of genome segments was demonstrated with purity up to 20% superior to the bench controls, proving thereby the suitability of the platform for synthetic biology applications.

**Keywords:** Synthetic biology – Microfluidics – Purification – Lab-on-a-Chip
I. Introduction

Synthetic Biology encompasses techniques and methods used to re-engineer biological units such as cells or organisms ([Carr and Church 2009](#)). To achieve this, synthetic biology engineers have created standardized biological units: bioparts or biobricks which assembly can be changed on demand using a standard, predictable, and therefore more reliable protocol. By being able to tune living systems, or create new synthetic biological systems, the production of materials such as medicines or biofuels from biological living organisms could be transformed or dramatically improved. In that respect synthetic genome segment assembly is currently used for the optimisation of various enzymatic pathways ([Boehm et al. 2013](#), [Smolke and Silver 2011](#)). As an example, the variation of major transcriptional regulators to perturb metabolisms is deemed to increase the yield of bacteria producing biofuels ([Colin et al. 2011](#)).

The design of genetic systems involves the synthesis and assembly of genome segments. While the oligo synthesis is performed by organic chemical reactions, a greater variety of protocols exist for joining or assembling larger DNA segments ([Carr and Church 2009](#)). Among others, ligation allows pooling assembly organisation and is the fastest method compared to serial, parallel or hierarchical assembly ([Carr and Church 2009](#)). At the heart of the ligation process is the use of short specific overhangs (commonly referred to as “sticky ends”, usually 2 to 4 nucleotides) and a DNA ligase enzyme to assemble DNA segments.

After or during assembly, some kind of error control needs to be put into place to remove unwanted or surplus oligos from the reaction mix and improve the reliability of the gene synthesis. This purification phase itself has also been reported to considerably enhance the reliability of the DNA assembly ([Tian et al. 2004](#)) and is the targeted application of the disposable chip presented in this article.

Efficient assembly and purification of large DNA segments towards genome replacement or
alteration needs automation and scale-up. Current mainstream technologies for automation involve conventional liquid handling robots which tend to be expensive. However, a series of new technologies, namely DNA microchips and microfluidic technologies have emerged in the last decade as a smart alternative to existing conventional technology [Fu et al. 2002; Wu et al. 2009a]. These platforms allow bioengineers (1) to go beyond the current throughput threshold in genome sequence assembly, (2) to provide reproducible and reliable processes, and (3) to reduce costs of failure and repeats due to human errors. To address these challenges, microfluidic platforms offer rapid and practical automation fully compatible with existing laboratory infrastructures such as liquid handling robots and microplate standards. Hence, microfluidic tools are highly desirable for automating biological and chemical protocols in order to avoid human errors, cross-contamination and lengthy procedures [Gulati et al. 2009; Szita et al. 2010; Vinuselvi et al. 2011]. In comparison to automated liquid handling robots, microfluidic systems also offer great advantages in parallelisation, throughput, miniaturisation and cost.

Several microfluidic platforms for biological protocol automation have been developed over the last decade [Balagadde et al. 2005; Gomez-Sjoeberg et al. 2007; Hong and Quake 2003; Lee et al. 2010; Wu et al. 2009b]. Microfluidic large scale integration (µLSI) was developed using pneumatically controlled micromechanical valves and pumps, enabling highly complex biological automation in parallel [Hong and Quake 2003]. The microfluidic valves are manufactured using multilayer soft-lithography with superimposed polydimethylsiloxane (PDMS) layers for manipulating liquids and gases [Squires and Quake 2005; Xia and Whitesides 1998]. The gas in the control channel applies a pneumatic pressure which bends the elastomer membrane over the flow channel in order to precisely control the flow of liquids. Similarly, microfluidic latches were developed using pneumatic vacuum [Grover et al. 2008; Zhang et al. 2009]. Furthermore, a number of these microfluidic platforms have
been demonstrated for synthetic biology applications. Zhou and colleagues demonstrated the synthesis and assembly of multiple DNA sequences in a microfluidic picoarray \cite{Zhou2004}. Kong et al demonstrated a parallel gene synthesis in 500 nL chambers which dramatically reduced by two orders of magnitude the volumes of reagents used \cite{Kong2007}. Multiplex gene synthesis have also been achieved using adapted protocols partly performed on DNA microchips \cite{Tian2004, Richmond2004}. A platform using electrowetting as the actuation method has demonstrated parallel DNA ligation in a 2.1µL reaction chamber \cite{Lin2011}. Another PDMS/glass chip assembly has recently demonstrated successful DNA ligation with optimised protocol timing (5 min) compared to its benchtop counterpart (4h) \cite{Ko2010}. However, these devices did not incorporate DNA error correction protocol.

Despite interesting characteristics, the use of PDMS presents several disadvantages: (i) high permeability of the material means that some specific design must be implemented to counteract the fast evaporation of small volumes of liquid \cite{Kong2007}, (ii) its compliance induces large variations in device performance (ie flow rate variability) and consequently PDMS is rarely a material of choice in industry unless for use of specific properties such as in Quakes’ valves \cite{Becker}. Although practical in terms of rapid-prototyping and its low cost, the use of PDMS in research laboratories has been largely questioned in recent years, and several alternatives providing higher Young’s modulus have been proposed \cite{Sollier2011}. Packaging is also a serious commercialisation issue for microfluidic systems \cite{Webb2009}, and for all of the techniques described above, common features such as direct plugs on chip for fluid introduction or pneumatic control bonded on chip are required. For some systems, up to hundreds of tubing connections have to be plugged onto a microfluidic chip every time a new chip is used, making this loading or unloading step time-consuming and
prone to human errors. In addition, fluidic connectors plugged directly on the chip hinder the direct loading or recovery of products by manual or robotic liquid systems. There is a real need for microfluidic platforms offering greater compatibility with high throughput robotic liquid systems for full automation.

To address these challenges, an alternative approach, named ‘Clamp n’Play’ is proposed. The Clamp n’Play approach is a plug-less clamped-based microfluidic chip, for full-scale biological protocol automation, using an integrated platform system with a user-friendly interface. Modular platforms based on pneumatic fluid actuation have been demonstrated in the past but they often integrate passive and active layers in one monolithic block. Some decoupled concepts have been proposed. For example, a modular platform and chips made of PDMS and silicon allowed the separation of actuators (active chip) from reactor (passive chips) \cite{shaikh2005}. However, the fluid circulates in the passive as well as the active re-usable chip, therefore contamination may occur in the non-disposable parts of the system.

Clamping systems have been in use in several microfluidic groups \cite{skaffe2013}, although no fully integrated platform with electro-mechanical actuators has been reported and validated with a synthetic biology application. The unique features of our approach are the combination of the following: (i) the separation or decoupling of the microfluidic device from its flow control components and microactuators allowing modularity, (ii) the isolation of the reaction layer from the actuation layer, eliminating sample contamination in the reusable parts (iii) high-throughput capabilities and (iv) compatibility with automated pipette loading. The functionality of the platform is successfully validated via the parallel purification of genome segments, using a 4-channel chip, prior to the complete assembly of a recombinant plasmid.

2. Materials and Methods

2.1. Fully decoupled microfluidic concept
The decoupling concept, illustrated in Fig. 1, employs a multi-layer, but physically detachable system. The chip contains a rigid layer (A) for the accurate alignment of the chip with the underlying platform, combined with an elastic and deformable layer (B) acting as a membrane for closing valves via pneumatic actuation as well as sealing the chip and isolating it from the platform. The membrane is flexible enough to bend and close the valve fully, yet strong enough to sustain repeated actuations. The flow inside the microfluidic channels is accurately controlled by a separate underlying control platform (C) which integrates an array of pneumatic microactuators for actuating the various elastic membranes of the system and magnetic and thermal actuators for performing biological reactions. No tubing connection is necessary on the microfluidic chip and the disposable passive part is simply clamped on a layer of silicone O-rings (Polymax, UK) embedded in the integrated control platform (not shown in Figure 1). Silicone O-rings allow a good seal at each of the chip-to-platform pneumatic connections. For scale-up purpose, the o-ring layer may be replaceable by a moulded elastomer layer. By decoupling the functions pertinent to the chip and control system, a simple low-cost polymeric chip can perform complex biological protocols involving pumping, mixing, reaction, and purification in a fully automated way.

2.2. Purification chip design

The architecture of the purification chip consists of four independent channels (250 µm width, 39 mm length), each having (i) an input and output well (4 mm in diameter, 4 mm depth), (ii) a pump featuring two valves and an actuation chamber, (iii) a reaction chamber (9 mm x 3 mm x 0.2 mm) and (iv) a back valve to isolate the reaction chamber from the output well. To make the chip fully compatible with existing fluid handling robotic solution, input and output holes or wells have been spaced with the standard 96-well plate pitch (Fig 1, bottom-right insert). The reservoirs on the microfluidic chip can be prefilled using manual or robotic pipetting mechanisms, thereby complying with existing laboratory equipment. The
number of channels was kept to four for simplicity and allowing for the parallel purification of the three genome segments (c.f. Biological Materials), plus a negative control. The chip footprint allows potential for scaling-up the number of channels to accommodate 16 channels. The chip fabrication is described in supplementary material.

2.3. Pneumatic, thermal and magnetic actuators and control

Accurate control of the micro-actuators is essential to the overall performance of the microfluidic device. In this study, compressed air actuators have been chosen for their maximal force and displacement. The platform itself includes the pneumatic channel layers, which have been cut in three 2mm thick PMMA layers bonded using Epoxy glue. This unit fits on a larger base with threaded ports to accommodate air connectors. This base is itself fixated on an optical table for ease of use and great stability. The electrovalves (D123201, Dynamco, US) placed on each side of the base were controlled via a Data Acquisition (NI cDAQ-9172, DAQ-9403) Card (NI, USA) and fed with 2 bar compressed air redistributed to the platform via several permanently attached tubing segments. Using the decoupling concept, other microcomponents can be added to the control platform without raising the cost of the disposable plastic chip. A Peltier device (ThermaTec HtHot, Melcor, UK) measuring 6mm x 6mm was mounted with a thermo couple (Labfacility, Farnell, UK). The Peltier device and thermo couple were placed below the reaction chambers to provide a specific temperature profile. Similarly, a magnetic control device was mounted on the platform for mixing and trapping purpose. Fig.1 shows the integration of a strong magnet on a robotic arm above the reaction chamber. Streptavidin coated magnetic beads (NEB, USA) were pumped into the reaction chamber with a conventional pumping cycle and trapped there via the placement of the magnet close to the chamber. The use of the magnetic beads is multifold. The motion of magnetic beads inside the reaction chamber increases the mixing and they allow the capture of biological components for magnetic activated separation. In order to
automate protocols and control in parallel the thermal profile, magnetic actuation and pumping, a custom-made Labview algorithm (LabVIEW 2008, NI) and a user-interface were developed. A snap-shot of the user-interface panel can be seen in supplementary information.

To assess the performance of the control platform and chip, a digital USB microscope (Dinolite, Big C, USA) was placed above the device to visualise real-time variations of the flow.

2.5. Biological Materials

For the genome segment assembly and purification experiments, DNA inserts and vectors, oligos and reagents were supplied by Gingko Inc. (Boston, USA) which included: (i) The high copy BioBrick™ assembly pSB1C3 plasmid [Che 2008] predigested with EarI used as a “backbone” vector for the assembly and carrying chloramphenicol resistance (ii) inserts coding for the green fluorescent protein (GFP) or red fluorescent protein (RFP), (iii) 4 part linkers or overhangs, and 4 purification oligos. Additionally, 15 to 30 µL of streptavidin coated magnetic beads solution (NEB, USA) with a diameter of 1µm were used for DNA capture during the purification experiment. NEB 10-beta competent E.Coli cells (NEB, USA) were used for the transformation of the genome assembly obtained and the verification of the functionality and purity of the off-chip and on-chip protocols. The high efficiency transformation protocol suggested by the manufacturer was followed. Cells were plated on Lysogeny broth (LB) Agar Plate with chloramphenicol (Technova, USA) and cultured for approximately 12 hours (overnight) at 37ºC. After 12 hours, plates were removed from the incubator and placed in a refrigerator for 4 hours. This step increased the fluorescence of the colonies. Colonies on each plate were inspected under UV light and counted. All cells visible on the plate carry chloramphenicol resistance, which mean they have been successfully transformed with the plasmid. Successful purification and final assembly of plasmid vector and inserts (GFP and RFP) lead to colonies exhibiting chloramphenicol resistance and a
modified strain (green or red colonies). Gel electrophoresis was first considered for a direct quantification of various DNA segment levels in and out of the chip. However, the detection of small levels of DNA segments was found be impossible to obtain, while a single plasmid can successfully transform one single cell. Therefore, the success of the purification was verified indirectly by establishing the ratio of colonies with the correct phenotype versus the total number of colonies in the plate after assembly. For illustration, a 50% ratio corresponds to half of the cell population being transformed by a plasmid exhibiting the antibiotic resistance and the modified strain (successful purification and ligation), while the other half of the population is exhibiting only the antibiotic resistance (unsuccessful purification leads to failed ligation between the plasmid backbone and RFP or GFP parts).

2.6. Genome segment assembly and two-part purification

In order to demonstrate the full functionality of the chip, the parallel purification of several genome segments was demonstrated and validated through the assembly of a plasmid backbone and a part coding for the red or green fluorescent protein, (RFP or GFP) as presented in Fig.2A. The pre-assembly, two-step purification and final assembly are briefly described. The first part of the assembly consists of a ligation to combine RFP and GFP parts with part linkers. This step is performed off-chip as described in [Che et al. 2012]. This is followed by a two-step sequential purification of the pre-assembled parts. The purpose of the purification is to wash and remove the unwanted or unbound oligos from the pre-assembled part mix. In a first instance, purification oligos and magnetic beads bind to one end of the pre-assembled parts (RFP or GFP parts and part linkers) and are retained via magnetic actuation in the reaction chamber, while unwanted and unbound oligos (part linkers) are washed away. In the second purification step, purification oligos and magnetic beads bind to the other end of the pre-assembled part and the remaining unbound oligos are washed away. The details of purification mechanisms will be fully published separately.
2.7. On-chip purification protocol

The microfluidic purification protocol detailed in Fig 2.b. is carried out in two chips to avoid contamination between the two steps. The second step of the on-chip purification protocol is identical to the first one but for two points. Firstly, the ligation mix was replaced by the elution product from the first step of the purification protocol and the purification oligos are different. Following the two-step microfluidic purification, a ligation reaction combines the purified plasmid and parts (GFP or RFP coding parts) into recombinant DNA which is transformed into competent E.Coli cells as described in the biological materials section. In parallel to all microfluidic experiments, bench-top controls using conventional bench fluid handling procedures such as pipettes and plate heaters were performed to provide performance comparison. For a fair comparison, the bench protocol followed closely the microfluidic protocol, using the same reagents volumes and waiting time. A negative control consisting of water was used in all experiments to verify the risk of contamination across the channels.

3. Results and discussion

3.1. Flow rate measurements

The effects of the pneumatic actuation frequency, fluid viscosity and thickness on the membrane on the flow rate produced were investigated. For this purpose, chips comprising two inlets, one outlet and a reaction chamber (as shown in the photograph insert in Figure 1) were fabricated. The chips were loaded with either water mixed with food dyes for visualisation or with 20% glycerol (V/V) (Sigma-Aldricht, UK) in water to assess the effect of liquid viscosity on the pumping performance. Investigating the chip performance under different viscosity is especially important for biological applications where products may be mixed with stabilising solutions at higher densities than water. Fig.3.a shows the evolution of
pumping flow rate as a function of the pumping frequency for different configurations. The highest pumping rate of 10 µLs⁻¹ was achieved for a pumping frequency of 100Hz, a membrane thickness of 50 µm and water. Above 100 Hz, the flow rate decreases as the membrane does not have the time to close properly the cavity during the pulse. Additionally the optimal frequency is also restricted by the solenoid valve response time, which was 9 ms for 111 Hz (Figure 3a). The same set-up was tested with a solution of glycerol in water (20%). Glycerol is commonly used in biological protocols, and we wanted to demonstrate the possibility to pump this material through the same system. The higher viscosity in the latter case reduced the flow rate to 8 µL/s and the optimal frequency was slightly shifted (110 Hz). However, due to a small data set, it is impossible to conclude whether this flow rate difference seen between the water and 20% glycerol mixture is statically significant and generalise this observation. The same chip design was tested with a thicker membrane (70 µm), however, the flow rate performance of the chip dropped dramatically below 3 µLs⁻¹. For the remainder of the study and biological characterisation, 50 µm thick membranes were used. A reliability study to compare the performance of a pump run after run was carried out. The inlet well was loaded with the same set volume each time, actuated with the same frequency and the time to empty the well was recorded. The inlet well was rinsed and carefully dried before a new run was started. The best reliability was achieved at low frequency (Relative Standard Deviation (RSD) as little as 1.1% for a pumping frequency of 1Hz (Figure 3.b)) and therefore the remainder of the study was performed between 1 and 5Hz.

3.2. Characterisation of Magnetic control

The use of streptavidin-coated magnetic beads is a central element of various biological purification protocols. Here the genome segments to be purified are captured and hold in the central chamber. 20 µL of 1 µm magnetic beads were pumped in the reaction chambers for
each purification step. A magnet was brought in close proximity to the reaction chambers (approximately 4mm). After a few seconds, all the magnetic beads were trapped in the chamber and the flow was reactivated. This succession of events is illustrated in Figure 4b. As the strength of the magnetic capture depends on the thickness of the PMMA substrate and the flow rate used, a window might be created in the PMMA substrate base layer above the chamber to allow a better magnetic trapping. In turn, a higher trapping force allows for the use of higher flow rate for washing steps. For a distance of 2 mm between the magnet and the chamber, the beads were held up to a driving frequency of approximately 4 Hz, effectively limiting the use of magnetic capture to flow rate below 1 µL.s⁻¹ [A video of the magnetic trapping under a 4Hz flow rate is showed in supplementary information]. Above this threshold, a proportion of the beads is slowly washed away towards the output well at each pump stroke and at flow rate. Above 20 µL.s⁻¹, magnetic beads can easily be flushed if the chip needs to be re-used.

3.3. Characterisation of temperature control

The elution of DNA molecules from Streptavidin coated magnetic beads necessitates a temperature of 65°C, which is provided by the Peltier device underneath the reaction chambers. To characterise the temperature control in the reaction chambers, thermochromic ink (Chromazone, UK) with a temperature of 47°C (±2°C) was used (Fig 4b). The small thermal mass of the reaction chamber combined with the control precision of the Peltier device allows a rapid and flexible temperature control in the reaction chamber. Even under a sustained flow rate (approximately 5 µL/s), the Peltier provided enough heat to maintain the desired temperature in the chamber (Fig 4.b-iii and suppl. material).

3.4. Biological validation with parallel genome segment purification

An assay for the parallel purification of genome segments was developed (cf Material and
Methods section), adapted for a microfluidic manipulation and used as the validation of the integrated platform and associated chip presented.

### 3.4.1. Influence of wash cycles on part purification

Up to 3 genome segments (backbone plasmid, RFP and GFP parts) parallel purification was demonstrated in the chip design outlined in section 2 and Figure 2. For all parts, the volume of washing buffer was found to be critical for purification performance. Fig. 5.A shows the purification improvement for washing volumes of 30 µL, 40 µL, 80 µL and 90 µL. The lowest purity of 57% is achieved for the smallest washing buffer volume (30 µL), while a purity above 90% is achieved for a volume of 90 µL. The purity linearly improves with the amount of washing buffer. These figures show that washing steps to remove unwanted oligos are the most critical steps in the on-chip protocol. Although it was found that larger washing volumes increase the purity of the final product, different optimisation strategies could reduce the volume actually needed to perform the washing; for example a reduction of the reaction chamber volume could enhance the mixing process. Furthermore, an improvement in purity was also noted with a change in the magnetic mixing regime, which might even further enhance the washing of unwanted oligos (data not shown). The whole single purification step took about 35 minutes, for all three genome segments to be purified in parallel. Comparatively, the duration of the “manual” bench control was longer as the magnetic actuation and elution steps have to be done serially for each tube.

### 3.4.2. Cross-contamination control

In the purification chip (Figures 1 and 2), each parallel channels are physically separated from one another. To study the possibility of cross-contamination via an exchange of solutions in the laminated layers or between wells, the fourth channel in the chip was always filed with DI water (negative control). This channel was actuated in the same way as the other channels, and sampled in the output well at the end of the purification protocol. A
ligation reaction with the content of the output well as insert and purified backbone plasmid as vector was carried out. It was expected that if contamination from adjacent wells containing GFP and RFP inserts was occurring, then colonies showing modified strain would grow on the control plate. Across all experiments carried out in this study, no contamination was found. A plate corresponding to this negative control is shown in Fig. 5.f. These results indicate that no contamination occurs via the laminated layers or input wells.

3.4.3. Validation of the platform for parallel genome segments purification

DNA purification using magnetic beads has been demonstrated in microfluidic chips by several groups [Karle et al. 2009, Oblath et al. 2013] in the context of DNA extraction from cells and prior to PCR. However, no parallel purification of several long genome segments (several kb) has been yet demonstrated in the context of synthetic biology. Here the challenge is not to extract DNA from a sample but to remove undesired oligos from a genome sequence mixture before gene synthesis. Undesired or unbound oligos otherwise threaten the performance of the final assembly or synthesis if not removed [Carr and Church 2009]. While in the first case (DNA extraction in prior to PCR), the performance of the chip will be assessed by directly measuring the amount of DNA extracted, in the later case the performance of the system is measured by transforming cells using the purified DNA to verify if all unwanted oligos have been removed from the initial mixture. Transformation results with RFP plasmids. The performances of the on-chip protocol are compared to the bench-top protocol for washing volumes of 90 µL. Both on-chip and bench-top control were performed on the same day and with the same reagents. The final assembled products were also transformed and cells plated on the same day. As shown in Figure 5.b, the on-chip protocol has comparable performance compared with the conventional protocol with respective ratio of cells with the correct phenotype: 91.85% (CV=2.47, N=2) and 90.15% (CV=2.19, N=2). In the absence of a robust statistical analysis due to a small data set, these
results show that the on-chip results are comparable to the bench control but may not be statistically different. Figures 5.d and 5.e display the transformed cells on agar plates. The associated negative control described earlier is shown in Figure 5f. In Figure 5.d the cells have been transformed with the recombinant DNA parts after a double purification on-chip, while in 5e, the cells are transformed using the off-chip derived products. The yield is on the same order of magnitude in both plates. **Transformation results with GFP plasmids.** In the transformations with the recombinant DNA containing the GFP insert the on-chip purification was found to be substantially more efficient by approximately 20% than the bench-top off-chip experiments (on-chip ratio of correct phenotypes: 75.4%, off-chip ratio of correct phenotypes: 58.3%, p-value = 0.007) (Figure 5.c). The two repeats of the on-chip and off-chip results were found to within the same range with a small coefficient of variation (on chip: CV=1.3, N=2; off-chip CV=1.3, N=2) indicating that this process might have a good overall repeatability. Generally, the purity of colonies with GFP parts was however lower than the purity of colonies with RFP parts (on average 16.5% lower for the on-chip process and 31.9% lower for the off-chip process). These differences with the RFP purification tests could be explained by a difference in transformation efficiencies of the competent cells used. However, even in the absence of a statistical analysis, these results indicate that the on-chip protocol could potentially outperform the conventional bench protocol. Further research is needed to increase the present data set and generalise these conclusions. **Channel-to-channel reproducibility.** On a chip, every channel and associated reaction chamber are expected to perform the same. In one experiment using 90 µL wash volumes, two RFP parts purifications were performed side-by-side in the middle channels. A variation of purity inferior to 2.7% was found between the two channels (which respectively led to 93.6 and 90.9% of correct phenotypes, bench control: 88.6%), indicating that good reproducibility of the process may be achievable across channels on one chip.
V. Conclusions

In conclusion, the microfluidic purification is identical or performs better (by up to 20%) than the conventional equivalent which validates the use of an automated microfluidic device and protocol for the parallel purification of genome segments for synthetic biology applications. The decoupling concept behind the platform permits the use of low-cost polymeric chips while allowing the process of complex biological protocols in an automated fashion. Although research and commercial solutions have been developed to alleviate the issue of sample introduction in the chip, including the Fluidigm chip kits and the CARD device from Rheonix, the system presented in this article is readily and fully compatible with existing liquid handling workstations to enable automated genome purification and assembly at a large range of volumes (~ 0.5 µL–1 mL). Temperature and magnetic controls have been integrated in the permanent platform and demonstrated with a simple chip design. The disposable chip is simply clamped in less than a few seconds onto the platform and does not require the plugging of any tubing. In this paper, we have demonstrated an application of this platform through the parallel purification of genome segments. Purification of up to four pre-assembled segments in parallel was achieved on-chip, although the throughput could easily be quadrupled, as the chip format allows up to 16 channels with the same features. Additionally, the throughput could even be higher if the dimensions of the wells (and scaled-down valves and other features) were spaced out with the standard 384-well plate pitch. Purification was demonstrated on-chip with up to 20% better purity compared to the bench-top equivalent protocol. DNA binding to the microfluidic material (PMMA, polymer membrane) should be taken into account and might need to be characterized in the future. The decoupled platform and its different actuation mechanisms are highly versatile many applications could benefit from this automated, small scale device including cell culture and portable diagnostics.
Acknowledgements

Funding from ITI/Scottish Enterprise for the Genome Segment Assembly programme is acknowledged. We thank Gingko Bioworks Inc. for supplying the biological reagents and DNA parts. The Advanced Manufacturing Centre at Heriot-Watt is acknowledged for the manufacturing of the mechanical parts. The thermochromic ink was provided by the company Chromazone Ltd.

Footnote

Conflicts of interest statement: WS and FA are founders and shareholders of Accufluidics Ltd. MKK, FA and WS have applied for several patents relating to the method described in this study. Other authors declare no conflict of interest.

References


List of Figures

Fig.1: Clamp n’Play modular platform concept. Schematic diagrams of the decoupling strategy with a bird-eye view of the disposable microfluidic chip and pneumatic integrated platform. The disposable chip is clamped into position on the control platform. After use, the chip is unclamped and disposed as biological waste. The circled letters describe: A) the disposable and detachable PMMA chip (total thickness, approximately 4.5 mm). For chip fabrication and details of the various layers, check supplementary material B) the elastomer membrane (approximately 50µm thickness) which seals the PMMA chip, isolates the chip from the platform while allowing fluid actuation via the platform C) the underlying permanent control platform with actuators (pneumatic, thermal and mechanical). The active control layer is isolated from the sample thereby eliminating the risk of sample-to-sample
contamination. The circled numbers describe: 1) An input well (total volume approx 50 µL) 2) A valve element (total volume approx 0.2 µL) 3) A pumping chamber (total volume approx 1 µL). The pump itself consists of two valve elements and a pumping chamber 4) A reaction chamber (total volume 5-20 µL) 5) An output well (identical to the input well) 6) Compressed air access for the opening and closure of the pneumatic actuators (valves and pumping chamber). X represents a closed valve, and O, an opened valve. The pumping pattern was XOO, XXO, OXO, OXX, OOX, XOX. By default, the valves and pumping chambers were kept closed. Inserts show (i) the temperature control under the reaction chamber. The use of a thermochromic ink with a temperature switch of 47°C allows the visualisation of the temperature variation. Here, a Peltier element is set at 49°C and flow is actuated with a 4 Hz frequency, (ii) the magnetic actuation for mixing and target capture in the reaction chamber. 10 µm streptavidin magnetic beads are trapped by the magnet and can be moved around in a pack and (iii) a disposable chip made of out PMMA and filled with red dye.

Figure 2: (a) Biological protocol from genome segment pre-assembly to transformation into competent cells. The parts are pre-assembled off-chip using overhangs (data not shown, refer to (Che et al. 2012) for a full description of the assembly process). The purification of four pre-assembled parts is performed in parallel on the integrated platform on a disposable chip. After the double-purification, a ligation reaction combines RFP or GFP inserts with plasmid PsB1C3 and the recombinant DNA is transformed in competent cells. The cells are plated on Agar plates and incubated for 12h, after which the colonies are observed UV light and counted using an imaging software. The first three steps with an asterisk are repeated for all the parts: RFP, GFP and the plasmid psB1C3. The purification of all parts is performed in parallel on a microfluidic chip (b) A simplified bi-microfluidic purification protocol in four steps. Stage I: Washing and magnetic bead loading. The four channels of the chip
were first washed with DI water to remove any unwanted particles after the fabrication. All the valves were closed, the magnet on the robotic arm was in place above the chamber and 20µL of streptavidin-coated magnetic beads were loaded into the wells by manual pipetting. The flow (4Hz) was activated until the input well was empty and the beads had travelled to the reaction chambers via parallel pneumatic actuation of the pumps. The output wells were regularly emptied with a pipette. The flow direction is indicated by an arrow. The magnet is placed above the reaction chambers to capture the beads. **Stage II: Oligo solution and binding buffer loading and mixing** 1µL of oligos solution was pipetted into all wells as well as an additional 10µL of binding buffer was pipetted into all the wells. These solutions were pumped into the reaction chamber; once the wells were emptied the actuation was stopped. The valves at the entrance and exit of the reaction chamber were closed and the magnet was moved linearly through robotic or manual control for about 30 s. The magnet was then moved away from the chamber and the mixture was incubated for 10 minutes at 20ºC. After incubation, the magnet was placed against the reaction chamber. **Stage III: Ligation mix loading, mixing and incubation.** Next, 1µL of NaCl solution and 10µL of ligation mix are introduced in the same way and the magnet is moved to allow the mixing of the reagents. The unbound oligos are washed away with a washing buffer (not shown, for volumes cf results). **Stage IV: Elution** 15µL of elution buffer was pipetted in each of the wells. About 5 µL of buffer was pumped into the reaction chamber and mixed gently using the magnet. The output wells were emptied. The heater was set to 65ºC and allowed to reach this temperature at which point the remainder of the input wells was pumped through. 10 µL of elution solution was pipetted from each output well and stored into labelled tubes for off-chip assembly.

**Figure 3:** Characterization of flow rate. (a) Influence of driving frequency and fluid viscosity on the flow rate. The experimental points are connected with a B-Spline function.
The star on each curve is a data point that marks the optimal frequency on each curve. (b) Performance variations of a pump at operational frequency of 1Hz. The error bars denote the Standard Deviation (n=5), of respectively 0.55, corresponding to a Relative Standard Variations (RSD) of 1.1%. The red line denotes the average across the control group.

**Figure 4: Magnetic and thermal actuation** (a) Photographs of the magnetic capture inside the chamber (a-i) the chamber filled with water (a-ii) the chamber filled with beads (a-iii) The chamber with the magnet applied and the beads aggregating. (b) Photographs of the chamber above the Peltier device, filled with thermochromic ink (Tt=47°C ±2°C). (b-i) Before the Peltier element is activated (b-ii) 10 s after the Peltier element is activated, the control temperature is 49°C, no flow (b-iii) Under a driving frequency of 4 Hz. For a video of (b-iii) refer to online supplementary material section.

**Figure 5: Validation of an integrated platform for on-chip purification of DNA segments** (a) Influence of the washing volumes on the purity in the RFP plasmid transformation. The highest washing volume (90 µL) gives the best result in terms of performance after assembly (93.6%) (b) Comparison of on-chip (93.6%, CV=2.47, N=2) and off-chip purity (88.6%, CV=2.19, N=2) after the assembly of the RFP parts in the plasmid vector. The difference between the two sets of data is not statistically significant with p-value = 0.7 (>0.01) (c) Comparison of on-chip (75.3%) and off-chip purity (58.3%) after the assembly of the GFP parts and plasmid vector. The difference between the two data sets is statically significant with a p-value=0.0075<0.005 (Student t-test, the data is representative of 2 independent experiments) (d) Plating results after transformation of competent E-Coli cells with recombinant DNA containing plasmid vector and RFP inserts purified on-chip. To facilitate the counting and visualisation, colonies exhibiting the RFP strain have been coloured using
open-source illustration software (ImageJ). The red arrows points on a colony with the modified strain. A white arrow points out on a colony with an un-modified strain (e) Plating results after transformation of competent E-Coli cells with recombinant DNA containing plasmid vector and RFP inserts purified off-chip (f) No cells are present in the negative water control, demonstrating the absence of cross-contamination between the parallel channels and thereby the absence of leakage which could occurred through delamination in the chip

Figure 1
Figure 2

Colony counting after 12h incubation

Purification step 1
- Streptavidin coated magnetic particle and purification oligo
- elution
- waste

Purification step 2
- Purified product
- elution
- waste

Ligation
- Plasmid
- psB1C3

Transformation
- Competent E.Coli cells
+ Assembled (recombinant) DNA
- Transformed cells

Cell culture
- LB Agar culture plate with chloramphenicol, 12 hours incubation at 37ºC

Parallel microfluidic purification step 1 or 2

Stage I
- Input reservoir
- Manual or automated pipetting

Stage II
- Reaction chamber
- Pump
- Valve network

Stage III
- Output reservoir
- Waste

Stage IV
- Manual or automated pipetting

On-chip operation
- Streptavidin coated magnetic beads
- Oligos and binding buffer
- NaCl and ligation mix
- Elution buffer
- Elution product

Off-chip operation
- Plasmid psB1C3
- GFP part
- RFP part
- Negative control

Manual or automated pipetting
Figure 3

![Graph showing flow rate vs. driving frequency for different fluids: Water, 50μm membrane; Glycerol 20%, 50μm membrane; Water, 70μm membrane.]

- Water, 50μm membrane
- Glycerol 20%, 50μm membrane
- Water, 70μm membrane

Figure 4

![Images of different samples labeled a-i, a-ii, a-iii, b-i, b-ii, b-iii.]

- a-i
- a-ii
- a-iii
- b-i
- b-ii
- b-iii
Figure 5

**a**

Percentage of relative cell number to exhibit RFP strain (%)

Washing volume (μL)

**b**

RFP results

<table>
<thead>
<tr>
<th>Washing Volume</th>
<th>On-chip</th>
<th>Off-chip</th>
</tr>
</thead>
<tbody>
<tr>
<td>30</td>
<td>8.1</td>
<td>91.9</td>
</tr>
<tr>
<td>40</td>
<td>9.8</td>
<td>90.2</td>
</tr>
</tbody>
</table>

Cells exhibiting only chloramphenicol resistance
Cells exhibiting chloramphenicol resistance and RFP strain
Cells exhibiting chloramphenicol resistance and GFP strain

**c**

GFP results

<table>
<thead>
<tr>
<th>Washing Volume</th>
<th>On-chip</th>
<th>Off-chip</th>
</tr>
</thead>
<tbody>
<tr>
<td>30</td>
<td>26.65</td>
<td>41.7</td>
</tr>
<tr>
<td>40</td>
<td>73.35</td>
<td>58.3</td>
</tr>
</tbody>
</table>


**d**

Plasmid psB1C3 + RFP part

Purification on-chip

Ligation

On-chip: 93.6%

**e**

Plasmid psB1C3 + RFP part

Purification off-chip

Ligation

Off-chip: 88.6%

**f**

Plasmid psB1C3 Negative control

Purification on-chip

Ligation

Negative control